Glycemia control and choice of antihyperglycemic therapy in patients with type 2 diabetes mellitus and COVID-19: a consensus decision of the board of experts of the Russian association of endocrinologists

Journal of diabetes mellitus Pub Date : 2022-03-23 DOI:10.14341/dm12873

И. Дедов, Г. Мокрышева, В. Шестакова, В. Никонова, Ю. Майоров, Г. Р. Галстян, М. Ш. Шамхалова, В. О. Барышева, А С Аметов, М. Б. Анциферов, А. Ю. Бабенко, Татьяна Бардымова, Ф. В. Валеева, А. А. Вачугова, Гринева, Т. Ю. Демидова, Т. П. Киселева, М. А. Куницына, Т. Н. Маркова, М. Мкртумян, Н. А. Петунина, Л. А. Руяткина, В. Салухов, Л. А. Суплотова, Л. Хадарцева, Ю Ш Халимов, I. Dedov, N. Mokrysheva, M. Shestakova, T. Nikonova, A. Mayorov, Galstyan, M. Shamkhalova, V. Barysheva, A. Ametov, Mikhail B. Antsiferov, Babenko, T. Bardymova, F. Valeeva, A. A. Vachugova, E. Grineva, T. Demidova, Tatiana P. Kiseleva, M. Kunitsyna, T. Markova, A. Mkrtumyan, N. Petunina, Ruyatkina, V. V. Saluhov, L. A. Suplotova, Elena L. Hadartseva

{"title":"Glycemia control and choice of antihyperglycemic therapy in patients with type 2 diabetes mellitus and COVID-19: a consensus decision of the board of experts of the Russian association of endocrinologists","authors":"И. Дедов, Г. Мокрышева, В. Шестакова, В. Никонова, Ю. Майоров, Г. Р. Галстян, М. Ш. Шамхалова, В. О. Барышева, А С Аметов, М. Б. Анциферов, А. Ю. Бабенко, Татьяна Бардымова, Ф. В. Валеева, А. А. Вачугова, Гринева, Т. Ю. Демидова, Т. П. Киселева, М. А. Куницына, Т. Н. Маркова, М. Мкртумян, Н. А. Петунина, Л. А. Руяткина, В. Салухов, Л. А. Суплотова, Л. Хадарцева, Ю Ш Халимов, I. Dedov, N. Mokrysheva, M. Shestakova, T. Nikonova, A. Mayorov, Galstyan, M. Shamkhalova, V. Barysheva, A. Ametov, Mikhail B. Antsiferov, Babenko, T. Bardymova, F. Valeeva, A. A. Vachugova, E. Grineva, T. Demidova, Tatiana P. Kiseleva, M. Kunitsyna, T. Markova, A. Mkrtumyan, N. Petunina, Ruyatkina, V. V. Saluhov, L. A. Suplotova, Elena L. Hadartseva","doi":"10.14341/dm12873","DOIUrl":null,"url":null,"abstract":"A dangerous viral disease COVID-19, caused by a new RNA coronavirus SARS-COV-2, has been actively spreading in the world since December 2019. The main manifestations of this disease are bilateral pneumonia, often accompanied by the development of acute respiratory syndrome and respiratory failure. Patients with diabetes mellitus (DM) are at high risk of infection with the SARS-COV-2 virus, severe illness and death.Maintaining of target glycemic levels is the most important factor in a favorable outcome of COVID-19 in both type 1 and type 2 DM. The choice of antihyperglycemic therapy in a patient with DM in the acute period of COVID-19 depends on the initial therapy, the severity of hyperglycemia, the severity of the viral infection and the patient’s clinical condition.The article presents the recommendations of the board of experts of the Russian Association of Endocrinologists on glycemic control and the choice of antihyperglycemic therapy in patients with type 2 DM and COVID-19, and also on the use of glucocorticosteroids used in the treatment of COVID-19 in patients with type 2 DM.","PeriodicalId":73708,"journal":{"name":"Journal of diabetes mellitus","volume":"39 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of diabetes mellitus","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14341/dm12873","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 4

Abstract

A dangerous viral disease COVID-19, caused by a new RNA coronavirus SARS-COV-2, has been actively spreading in the world since December 2019. The main manifestations of this disease are bilateral pneumonia, often accompanied by the development of acute respiratory syndrome and respiratory failure. Patients with diabetes mellitus (DM) are at high risk of infection with the SARS-COV-2 virus, severe illness and death.Maintaining of target glycemic levels is the most important factor in a favorable outcome of COVID-19 in both type 1 and type 2 DM. The choice of antihyperglycemic therapy in a patient with DM in the acute period of COVID-19 depends on the initial therapy, the severity of hyperglycemia, the severity of the viral infection and the patient’s clinical condition.The article presents the recommendations of the board of experts of the Russian Association of Endocrinologists on glycemic control and the choice of antihyperglycemic therapy in patients with type 2 DM and COVID-19, and also on the use of glucocorticosteroids used in the treatment of COVID-19 in patients with type 2 DM.

查看原文本刊更多论文

2型糖尿病合并COVID-19患者的血糖控制和降糖治疗选择:俄罗斯内分泌学家协会专家委员会的共识决定

由新型RNA冠状病毒SARS-COV-2引起的危险病毒性疾病COVID-19自2019年12月以来一直在全球积极传播。本病主要表现为双侧肺炎，常伴有急性呼吸综合征和呼吸衰竭的发展。糖尿病患者是SARS-COV-2感染、重症和死亡的高危人群。维持目标血糖水平是1型和2型糖尿病患者COVID-19预后良好的最重要因素。COVID-19急性期DM患者的降糖治疗选择取决于初始治疗、高血糖严重程度、病毒感染严重程度和患者的临床情况。本文介绍了俄罗斯内分泌学家协会专家委员会对2型糖尿病和COVID-19患者血糖控制和降糖治疗选择的建议，以及2型糖尿病患者治疗COVID-19时使用糖皮质激素的建议。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of diabetes mellitus

自引率

0.00%

发文量